Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe

MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy for PTSD. The team at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London – South London and Maudsley NHS Trust (KCL-SLaM) led by Dr. James Rucker and supported by the UK Chief Investigator Prof. Allan Young, expect to see their first patients in April.